These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

725 related items for PubMed ID: 20582477

  • 1. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
    Sung ES, Kim A, Park JS, Chung J, Kwon MH, Kim YS.
    Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
    [Abstract] [Full Text] [Related]

  • 2. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
    Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK.
    Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296
    [Abstract] [Full Text] [Related]

  • 3. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
    Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O.
    J Gene Med; 2007 Jun; 9(6):440-51. PubMed ID: 17410615
    [Abstract] [Full Text] [Related]

  • 4. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway.
    Tsapis M, Lieb M, Manzo F, Shankaranarayanan P, Herbrecht R, Lutz P, Gronemeyer H.
    Int J Biochem Cell Biol; 2007 Jun; 39(7-8):1500-9. PubMed ID: 17499001
    [Abstract] [Full Text] [Related]

  • 5. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
    Mühlethaler-Mottet A, Flahaut M, Bourloud KB, Auderset K, Meier R, Joseph JM, Gross N.
    BMC Cancer; 2006 Aug 24; 6():214. PubMed ID: 16930472
    [Abstract] [Full Text] [Related]

  • 6. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
    Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T.
    Oncogene; 2004 Aug 19; 23(37):6261-71. PubMed ID: 15208660
    [Abstract] [Full Text] [Related]

  • 7. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.
    Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P, La Porta CA.
    Apoptosis; 2004 Sep 19; 9(5):573-82. PubMed ID: 15314285
    [Abstract] [Full Text] [Related]

  • 8. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
    Iacomino G, Medici MC, Russo GL.
    Anticancer Res; 2008 Sep 19; 28(2A):855-64. PubMed ID: 18507029
    [Abstract] [Full Text] [Related]

  • 9. Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.
    Akahane K, Inukai T, Zhang X, Hirose K, Kuroda I, Goi K, Honna H, Kagami K, Nakazawa S, Endo K, Kubota T, Yagita H, Koyama-Okazaki T, Sugita K.
    Exp Hematol; 2010 Oct 19; 38(10):885-95. PubMed ID: 20670671
    [Abstract] [Full Text] [Related]

  • 10. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
    Nawrocki ST, Carew JS, Douglas L, Cleveland JL, Humphreys R, Houghton JA.
    Cancer Res; 2007 Jul 15; 67(14):6987-94. PubMed ID: 17638911
    [Abstract] [Full Text] [Related]

  • 11. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1355-64. PubMed ID: 16489094
    [Abstract] [Full Text] [Related]

  • 12. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K, Douglas L, Delaney A, Houghton JA.
    Clin Cancer Res; 2004 Oct 01; 10(19):6650-60. PubMed ID: 15475455
    [Abstract] [Full Text] [Related]

  • 13. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M, Meuleman N, Kentos A, Martiat P, Willems L, Bron D.
    Exp Hematol; 2007 Oct 01; 35(10):1527-37. PubMed ID: 17697742
    [Abstract] [Full Text] [Related]

  • 14. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis.
    Morales JC, Ruiz-Magaña MJ, Carranza D, Ortiz-Ferrón G, Ruiz-Ruiz C.
    Cancer Lett; 2010 Nov 01; 297(1):91-100. PubMed ID: 20580868
    [Abstract] [Full Text] [Related]

  • 15. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
    Choi SY, Kim MJ, Chung HY, Lee SJ, Jang YJ.
    Oncol Rep; 2007 Jan 01; 17(1):175-84. PubMed ID: 17143496
    [Abstract] [Full Text] [Related]

  • 16. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells.
    Hao JH, Yu M, Liu FT, Newland AC, Jia L.
    Cancer Res; 2004 May 15; 64(10):3607-16. PubMed ID: 15150119
    [Abstract] [Full Text] [Related]

  • 17. An agonistic antibody to human death receptor 4 induces apoptotic cell death in head and neck cancer cells through mitochondrial ROS generation.
    Lee BS, Kang SU, Hwang HS, Kim YS, Sung ES, Shin YS, Lim YC, Kim CH.
    Cancer Lett; 2012 Sep 01; 322(1):45-57. PubMed ID: 22353688
    [Abstract] [Full Text] [Related]

  • 18. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP, Zisman A, Bonavida B.
    Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.